The S&P/ASX 200 Index (ASX: XJO) has provided solid returns over the ultra-long term, but there are some ASX shares that could outperform the ASX 200.

We’re going to look at two ASX shares that could deliver great returns in the year ahead.

A price target suggests where experts think the share price will go over the next 12 months. Let’s look at two where analysts are expecting the share price to rise by at least 50%. That’s not a guaranteed return of course, just a prediction.

Coronado Global Resources Inc (ASX: CRN)

Coronado Global Resources describes itself as a leading international producer of high-quality metallurgical coal, which is an important aspect in the production of steel. It currently has operations in both Australia and the US.

According to CMC Invest, there have been five analyst ratings on the business within the last three months. Of those, one is a buy, and four are hold ratings. However, given that the Coronado Global Resources share price has dropped by more than 50% in 2026 to date, analysts now seem to think the business is noticeably undervalued.

The average price target of those five analysts is 31 cents, implying a possible rise of around 80% within the next year, according to CMC Invest.

Coronado recently announced that it was selling its 100% interest of the Logan Mining Complex to Phoenix Coal.

This transaction is expected to help the company’s free cash flow by reducing ongoing care, maintenance and holding costs, eliminating reclamation and other future mine obligations, and allowing Coronado to focus capital allocation on its core metallurgical coal operations.

The ASX share is also going through a structural reset to boost cash flow including a mine optimisation plan for Curragh, an improvement of fleet productivity, underground optimisation for Mammoth, and contract resets and management.

WiseTech Global Ltd (ASX: WTC)

Another ASX share that could produce good returns is WiseTech, a software provider for the logistics, global trade and supply chain industries worldwide.

It provides software for more than 22,000 logistics companies and other industry participants across 193 countries. Customers include 46 of the top 50 global third-party logistics providers and 23 of the 25 largest freight forwarders worldwide.

According to CMC Invest, within the last three months, there have been 10 analyst ratings on the business, with nine buy ratings and one hold rating.

The average price target is $67.65, suggesting an increase of more than 70% from where it is at the time of writing.

It recently jumped after announcing that Raelene Murphy would become the company’s independent chair, while Richard White will focus on his role as chief innovation officer and remain as an executive director.

White said that recent media attention on him is creating an unnecessary distraction from the strength of the WiseTech business. He also denied the allegations in the media.

WiseTech also said it continues to focus its search for an additional independent non-executive director and on long-term executive succession planning.

While the e2open acquisition created some short-term financial headwinds for the statutory net profit, the company’s organic growth remains solid. HY26 organic revenue rose 7%, organic operating profit (EBITDA) grew 7%, operating cash flow rose 14% and free cash flow increased 24%.

If it continues growing its cash flow by double digits, it could go a long way to justify the analysts’ optimism about the business.

Of course, these aren’t the only two ASX shares with a compelling outlook to watch.

The post 2 ASX shares tipped to grow 50% or more in the next 12 months appeared first on The Motley Fool Australia.

More reading

• These ASX tech shares crashed hard. Could they double from here?
• Here are the top 10 ASX 200 shares today
• WiseTech shares surge 10% as Richard White steps back from chair role
• Are WiseTech shares ripe for a rebound?
• How to tell if an ASX share is cheap or a value trap

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Looking for big returns? If you are, then it could be worth checking out the two ASX shares in this article.

That’s because analysts have just put buy ratings on them and are expecting upside of at least 20% from current levels.

Here’s what they are recommending:

Netwealth Group Ltd (ASX: NWL)

Bell Potter thinks this ASX share could be being undervalued by the market, especially after a strong quarterly update this week.

In response to its update, the broker has retained its buy rating and $30.00 price target on Netwealth’s shares. Based on its current share price of $24.43, this implies potential upside of over 20% for investors over the next 12 months.

Commenting on its recommendation, Bell Potter said:

NWL has provided an update across multiple fronts, highlights being the first material endorsement of its new private wealth and stockbroking solution, as well as long-term ambitions for the group. This includes more advanced net flow guardrails. We expect the conversation to move towards growth (and away from dissecting margins). The update sees net flows revised up, after delivering periods of $15B. We expect this will release doubts around governance, market volatility and proposed tax changes.

Our Buy rating is unchanged, and we upgrade our net flow estimates +8% FY27-29. Building in margin guidance prompts us to downgrade EPS -7%/-4% and we leave headroom on the FUA target. NWL is looking to replicate EPS growth. The mandate win is the first example of a catalyst, independent of any potential vendor attrition.

ResMed Inc. (ASX: RMD)

Morgans highlights that this sleep disorder treatment company’s shares have de-rated to their lowest PE ratio since the GFC.

As a result, the broker believes a buying opportunity has opened up and has put a buy rating and $41.72 price target on its shares. Based on its current share price of $31.44, this implies potential upside of approximately 33%.

Commenting on ResMed shares and its buy thesis, Morgans said:

RMD has de-rated to ~16x forward earnings, its lowest valuation since the post-GFC period, despite consensus continuing to forecast double-digit EPS growth. GLP-1 therapies, positive Phase III data from Apnimed’s oral OSA therapy, the prospect of Philips re-entering the US PAP market from 2027 and broader healthcare sector de-rating, have driven recent share price weakness.

While these risks are real, current industry data and RMD’s operating performance provide limited evidence of a material deterioration in underlying demand. We make no changes to FY26-28 forecasts or our A$41.72 target price. BUY.

The post Why these ASX shares could rise 20% to 30% appeared first on The Motley Fool Australia.

More reading

• Broker tips 20% and 23% upside for these 2 ASX stocks
• New parents are now earning superannuation on parental leave. Here’s how to make the most of it
• Why I want to own these ASX shares brokers rate as buys
• 5 things to watch on the ASX 200 on Wednesday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Netwealth Group and ResMed. The Motley Fool Australia has positions in and has recommended Netwealth Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If I had $2,000 to invest in ASX growth shares this July, I would be looking for businesses where the long-term opportunity looks strong and the valuation is attractive.

Here are two ASX growth shares I think tick those boxes and would consider buying today.

Catapult Sports Ltd (ASX: CAT)

Catapult Sports is a growth share I think is much more interesting than the current share price suggests.

The company provides wearable technology, video analysis, and performance software used by professional sporting teams around the world. Its technology helps coaches and performance staff understand player workload, improve training programs, analyse tactics, and make better decisions around athlete management.

What I like about Catapult is that it solves a very specific problem. Elite sports teams are constantly looking for small advantages. A better understanding of player fatigue, a more effective training session, or improved tactical analysis can influence results.

That means the technology is not just a nice addition. It can become part of how teams operate.

I also think the long-term opportunity is larger than many investors realise. Professional sport is becoming increasingly data-driven across football, rugby, basketball, American football, cricket, and many other competitions. The best teams are looking for more information, not less. This could result in growing demand for Catapult’s products over the next decade.

The shares are down around 55% from their highs, which has clearly damaged investor confidence. But I think that creates an opportunity to look beyond the short-term sentiment and focus on the underlying business.

SiteMinder Ltd (ASX: SDR)

SiteMinder is another ASX growth share I think has an interesting long-term story.

The company provides technology that helps hotels manage their online presence, connect with booking channels, improve direct bookings, and manage their rooms more effectively.

I think this is a fascinating part of the travel industry because it focuses on the behind-the-scenes technology that makes bookings possible.

Hotels compete for customers every day. They need to manage pricing, availability, online channels, and customer relationships across an increasingly digital environment. SiteMinder helps simplify that process.

What I like about the company is that it sits in the middle of a major industry shift. Travel has become more technology-driven, and accommodation providers need better tools to compete.

The artificial intelligence opportunity is also interesting. As hotels look for more automation and smarter ways to manage demand, software platforms that can provide better insights and efficiency could become increasingly valuable.

The shares are down around 50% from their 52-week high, and the business still needs to prove it can deliver sustainable profitable growth. But I think the long-term opportunity remains attractive. The hotel industry is huge, and the technology behind every booking is becoming more important.

Foolish takeaway

I think Catapult and SiteMinder are two examples of growth companies where the market may be focused more on the present than the future.

Both businesses are still building their stories, and execution will remain important.

But I like companies that solve real problems in growing industries. Catapult is helping professional teams make better decisions, while SiteMinder is helping accommodation providers compete in a more digital world.

Those are the types of growth opportunities I would be happy to own for the long term.

The post 2 ASX growth shares down 50%+ that I’d buy with $2,000 in July appeared first on The Motley Fool Australia.

More reading

• These ASX tech shares crashed hard. Could they double from here?
• How should I invest my money in FY27?
• This beaten-down ASX tech share could rise almost 50%
• 5 things to watch on the ASX 200 on Thursday
• Buy, hold, sell: Catapult Sports, Amcor, Transurban shares

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Catapult Sports and SiteMinder. The Motley Fool Australia has positions in and has recommended Catapult Sports and SiteMinder. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.